Respiratory Tract Infections

Respiratory·MeSH: Respiratory Tract Infections

Prevalence

2361.8 / 100K

Incidence

171074.6 / 100K/yr

8 drugs in development·6 companies·3 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
amoxicillin	Aptinyx Inc. (APTX)
amoxicillin	SUNSET ISLAND GROUP (SUN)
ceftriaxone	Teva Pharmaceutical Industries Limited (TEVA)
Double - Coptis Suppository	China Health Industries Holdings, Inc. (CHHE)
Double-Coptis Suppository	China Health Industries Holdings, Inc. (CHHE)
erythromycin lactobionate	NEXUS BIOPHARMA INC (NEXS)
minocycline	NEXUS BIOPHARMA INC (NEXS)
tobramycin	Amneal Pharmaceuticals, Inc. (AMRX)

BioSniper tracks 8 drugs in development for Respiratory Tract Infections across 6 companies.

There are 3 clinical trials targeting Respiratory Tract Infections tracked by BioSniper.

The estimated prevalence of Respiratory Tract Infections is approximately 2361.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.